Cargando…
Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in Europe; however, it is important to understand how clinical practice patterns differ between countries and how this might relate to disease outcomes, to identify ways of improving local disease management....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367183/ https://www.ncbi.nlm.nih.gov/pubmed/35944943 http://dx.doi.org/10.1136/bmjresp-2021-001150 |
_version_ | 1784765731304374272 |
---|---|
author | Whittaker, Hannah Van Ganse, Eric Dalon, Faustine Nolin, Maeva Marant-Micallef, Claire Pison, Christophe Ryan, Dermot P Deslee, Gaetan Quint, Jennifer K Belhassen, Manon |
author_facet | Whittaker, Hannah Van Ganse, Eric Dalon, Faustine Nolin, Maeva Marant-Micallef, Claire Pison, Christophe Ryan, Dermot P Deslee, Gaetan Quint, Jennifer K Belhassen, Manon |
author_sort | Whittaker, Hannah |
collection | PubMed |
description | INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in Europe; however, it is important to understand how clinical practice patterns differ between countries and how this might relate to disease outcomes, to identify ways of improving local disease management. We aimed to describe and compare the management of patients with COPD in the UK and France between 2008 and 2017. METHODS: We used data from the Clinical Practice Research Datalink GOLD and Hospital Episode Statistics in the UK and the Echantillon Généraliste des Bénéficiaire in France to identify patients with COPD each year between 2008 and 2017. We compared patient characteristics, all-cause mortality and COPD exacerbations each year between 2008 and 2017 for patients in the UK and France separately. Health care utilisation and COPD exacerbations in 2017 were compared between France and the UK using t-tests and χ(2) tests. RESULTS: Patients with COPD were similar in gender and comorbidities in both countries. Incidence of COPD exacerbations remained stable in the UK and France between 2007 and 2017. In 2017, the proportion of all-cause and COPD-related hospitalisations was greater in the UK than in France (43.9% vs 32.8% and 8.3% vs 4.9%, respectively; p<0.001) as was the proportion of patients visiting accident and emergency (A&E) (39.8% vs 16.2%, respectively; p<0.001). In addition, the mean length of stay in hospital for COPD-related causes was shorter in the UK than in France (6.2 days (SD 8.4) vs 10.5 days (SD 9.1), respectively; p<0.001). DISCUSSION: Overall, UK patients were more likely to go to A&E, be hospitalised for COPD-related causes and stay in hospital for fewer days after being admitted for COPD-related reasons compared with patients in France, illustrating a difference in health-seeking behaviours and access to healthcare. |
format | Online Article Text |
id | pubmed-9367183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-93671832022-08-22 Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France Whittaker, Hannah Van Ganse, Eric Dalon, Faustine Nolin, Maeva Marant-Micallef, Claire Pison, Christophe Ryan, Dermot P Deslee, Gaetan Quint, Jennifer K Belhassen, Manon BMJ Open Respir Res Chronic Obstructive Pulmonary Disease INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in Europe; however, it is important to understand how clinical practice patterns differ between countries and how this might relate to disease outcomes, to identify ways of improving local disease management. We aimed to describe and compare the management of patients with COPD in the UK and France between 2008 and 2017. METHODS: We used data from the Clinical Practice Research Datalink GOLD and Hospital Episode Statistics in the UK and the Echantillon Généraliste des Bénéficiaire in France to identify patients with COPD each year between 2008 and 2017. We compared patient characteristics, all-cause mortality and COPD exacerbations each year between 2008 and 2017 for patients in the UK and France separately. Health care utilisation and COPD exacerbations in 2017 were compared between France and the UK using t-tests and χ(2) tests. RESULTS: Patients with COPD were similar in gender and comorbidities in both countries. Incidence of COPD exacerbations remained stable in the UK and France between 2007 and 2017. In 2017, the proportion of all-cause and COPD-related hospitalisations was greater in the UK than in France (43.9% vs 32.8% and 8.3% vs 4.9%, respectively; p<0.001) as was the proportion of patients visiting accident and emergency (A&E) (39.8% vs 16.2%, respectively; p<0.001). In addition, the mean length of stay in hospital for COPD-related causes was shorter in the UK than in France (6.2 days (SD 8.4) vs 10.5 days (SD 9.1), respectively; p<0.001). DISCUSSION: Overall, UK patients were more likely to go to A&E, be hospitalised for COPD-related causes and stay in hospital for fewer days after being admitted for COPD-related reasons compared with patients in France, illustrating a difference in health-seeking behaviours and access to healthcare. BMJ Publishing Group 2022-08-09 /pmc/articles/PMC9367183/ /pubmed/35944943 http://dx.doi.org/10.1136/bmjresp-2021-001150 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Chronic Obstructive Pulmonary Disease Whittaker, Hannah Van Ganse, Eric Dalon, Faustine Nolin, Maeva Marant-Micallef, Claire Pison, Christophe Ryan, Dermot P Deslee, Gaetan Quint, Jennifer K Belhassen, Manon Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France |
title | Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France |
title_full | Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France |
title_fullStr | Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France |
title_full_unstemmed | Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France |
title_short | Differences in severe exacerbations rates and healthcare utilisation in COPD populations in the UK and France |
title_sort | differences in severe exacerbations rates and healthcare utilisation in copd populations in the uk and france |
topic | Chronic Obstructive Pulmonary Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367183/ https://www.ncbi.nlm.nih.gov/pubmed/35944943 http://dx.doi.org/10.1136/bmjresp-2021-001150 |
work_keys_str_mv | AT whittakerhannah differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance AT vanganseeric differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance AT dalonfaustine differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance AT nolinmaeva differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance AT marantmicallefclaire differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance AT pisonchristophe differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance AT ryandermotp differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance AT desleegaetan differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance AT quintjenniferk differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance AT belhassenmanon differencesinsevereexacerbationsratesandhealthcareutilisationincopdpopulationsintheukandfrance |